Luby J P, Ware A J, Vergne-Marini P, Stastny P, Hull A R
Arch Intern Med. 1979 Jan;139(1):33-5.
Rubella antibody titers were determined pretransplant and then serially posttransplantation in 52 consecutive patients whose renal allografts survived at least three months. Group A patients (18) had antibody titers greater than or equal to 1:128 in the posttransplant period. Group B (24) had intermediate antibody titers that never rose higher than 1:64. Group C (10) consistently had antibody titers less than 1:8. Group A did not differ from groups B and C with respect to age, race, sex, type of transplant, underlying renal disease, or maximum complement fixation antibody titers posttransplant to cytomegalovirus or herpes simplex virus, type 1. Group A did differ from groups B and C in its frequency of hepatitis, chronic liver disease, episodes of late rejection (greater than or equal to 21 days after transplant), transplant nephrectomy required for rejection, infections whose defense involves intact cell-mediated immunity, and the number of late rejection episodes per patient. Mechanisms underlying these associations are not known but apparently are not related to HLA phenotype.
对52例肾移植存活至少3个月的连续患者在移植前测定风疹抗体滴度，然后在移植后连续测定。A组（18例）患者在移植后时期抗体滴度大于或等于1:128。B组（24例）抗体滴度中等，从未高于1:64。C组（10例）抗体滴度始终低于1:8。A组在年龄、种族、性别、移植类型、潜在肾病或移植后对巨细胞病毒或1型单纯疱疹病毒的最大补体结合抗体滴度方面与B组和C组无差异。A组在肝炎、慢性肝病、晚期排斥反应（移植后大于或等于21天）的发生率、因排斥反应需要进行移植肾切除术、防御涉及完整细胞介导免疫的感染以及每位患者的晚期排斥反应发作次数方面与B组和C组不同。这些关联的潜在机制尚不清楚，但显然与HLA表型无关。
